"Vaccines, Conjugate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
| Descriptor ID |
D018074
|
| MeSH Number(s) |
D20.215.894.865.900 D23.050.865.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Conjugate".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Conjugate".
This graph shows the total number of publications written about "Vaccines, Conjugate" by people in this website by year, and whether "Vaccines, Conjugate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 2 | 4 |
| 2006 | 0 | 6 | 6 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 3 | 6 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 5 | 7 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 5 | 7 |
| 2020 | 1 | 5 | 6 |
| 2021 | 4 | 2 | 6 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 7 | 7 |
| 2024 | 2 | 4 | 6 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Conjugate" by people in Profiles.
-
Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project. J Infect. 2025 Mar; 90(3):106426.
-
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
-
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025 Apr; 25(4):457-470.
-
Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children. Nat Commun. 2024 Sep 27; 15(1):8401.
-
Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005-19: a cohort observational study. Lancet Glob Health. 2024 Sep; 12(9):e1470-e1484.
-
Geographical migration and fitness dynamics of Streptococcus pneumoniae. Nature. 2024 Jul; 631(8020):386-392.
-
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis. Health Technol Assess. 2024 Jul; 28(34):1-109.
-
Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones. Vaccine. 2024 May 22; 42(14):3337-3345.
-
Potential for Maternally Administered Vaccine for Infant Group B Streptococcus. N Engl J Med. 2023 Jul 20; 389(3):215-227.
-
Streptococcus pneumoniae and other bacterial nasopharyngeal colonization seven years post-introduction of 13-valent pneumococcal conjugate vaccine in South African children. Int J Infect Dis. 2023 Sep; 134:45-52.